Theriva Biologics (TOVX) Interest & Investment Income (2011 - 2026)
Theriva Biologics (TOVX) posted quarterly Interest & Investment Income of $82000.0 for Q1 2026, down 14.58% year-over-year from $96000.0 in Q1 2025, and up 13.89% quarter-over-quarter from $72000.0 in Q4 2025.
Theriva Biologics (TOVX) Interest & Investment Income (2011 - 2026) Analysis & Trends
Theriva Biologics (TOVX) has reported Interest & Investment Income for 16 consecutive years, with $82000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest & Investment Income fell 14.58% year-over-year to $82000.0; the TTM figure through Mar 2026 stood at $273000.0 (down 51.68% YoY), while the FY2025 annual figure was $287000.0, down 58.82% from the prior year.
- Interest & Investment Income rose to $82000.0 in Q1 2026 per TOVX's latest filing, from $72000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $382000.0 in Q3 2023 and bottomed at $2000.0 in Q1 2022.
- Historically, Interest & Investment Income has averaged $177529.4 across 5 years, with a median of $158000.0 in 2024.
- Annual changes were most pronounced in 2023 — Interest & Investment Income soared 18100.0% — and 2025, when it plunged 68.79%.
- Theriva Biologics' Interest & Investment Income stood at $315000.0 in 2022, then decreased by 0.95% to $312000.0 in 2023, then plunged by 55.77% to $138000.0 in 2024, then slumped by 47.83% to $72000.0 in 2025, then grew by 13.89% to $82000.0 in 2026.
- Business Quant data shows TOVX's Interest & Investment Income at $82000.0 in Q1 2026, $72000.0 in Q4 2025, and $65000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Theriva Biologics | 10.64 Mn | 10.64 Mn | - | 79,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 79,000.00 |
| Mar 31, 2026 | 82,000.00 |
| Dec 31, 2025 | 72,000.00 |
| Sep 30, 2025 | 65,000.00 |
| Jun 30, 2025 | 54,000.00 |
| Mar 31, 2025 | 96,000.00 |
| Dec 31, 2024 | 138,000.00 |
| Sep 30, 2024 | 158,000.00 |
| Jun 30, 2024 | 173,000.00 |
| Mar 31, 2024 | 228,000.00 |
| Dec 31, 2023 | 312,000.00 |
| Sep 30, 2023 | 382,000.00 |
| Jun 30, 2023 | 381,000.00 |
| Mar 31, 2023 | 364,000.00 |
| Dec 31, 2022 | 315,000.00 |
| Sep 30, 2022 | 170,000.00 |
| Jun 30, 2022 | 26,000.00 |
| Mar 31, 2022 | 2,000.00 |
| Dec 31, 2021 | 2,000.00 |
| Sep 30, 2021 | 2,000.00 |